Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study
Titel:
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study
Auteur:
Gelderblom, Hans Jones, Robin L. Blay, Jean-Yves George, Suzanne von Mehren, Margaret Zalcberg, John R. Kang, Yoon-Koo Razak, Albiruni Abdul Trent, Jonathan Attia, Steven Le Cesne, Axel Siontis, Brittany L. Goldstein, David Boye, Kjetil Sanchez, Cesar Steeghs, Neeltje Rutkowski, Piotr Druta, Mihaela Serrano, César Somaiah, Neeta Chi, Ping Harrow, Brooke Becker, Claus Reichmann, William Sherman, Matthew L. Ruiz-Soto, Rodrigo Heinrich, Michael C. Bauer, Sebastian